adobe stock photos - JustlightHypertensionAZ’s baxdrostat mets endpoint in resistant hypertensionAstraZeneca’s baxdrostat cuts 24-hour systolic BP by 14mmHg in resistant hypertension, offering a novel mechanism and major market potential. more ➔
stock.adobe.photos.com - gaviLicencing dealAstraZeneca bolsters obesity portfolio with muscle‑preserving buyAstraZeneca plc acquires SixPeaks Bio Inc to target muscle‑preserving obesity therapies, boosting its pipeline in a US$30 bn fast-growing weight-loss market. more ➔
adobe stock photos - AkuAku mRNA ProductionBreakthrough study reveals stability key for mRNAA landmark discovery by a team of South Korean scientists could transform the way RNA-based vaccines and therapeutics are developed and produced. Researchers led jointly by Professor V. Narry Kim and … more ➔
Adobe stock photos - Dzmitry Obesity medicinesSemaglutide and tirzepatide significantly improve heart healthSemaglutide (Ozempic®) and Tirzepatide (Mounjaro®) not only promote weight loss but also significantly reduce the risk of major cardiovascular events in patients with type 2 diabetes. Real-world evidence … more ➔
Adobe stock photos - Matthew US Pharma PricesEli Lilly and Novo Nordisk slash obesity drug pricesEli Lilly and Novo Nordisk cut US obesity drug prices under Trump’s MFN plan, offering Zepbound, Wegovy and others via Medicare, Medicaid and LillyDirect. more ➔
Parse BiosciencesAI/single cell analysisQIAGEN acquires Parse Biosciences Inc for US$225mBiotech leader QIAGEN NV announced the acquisition of Parse Biosciences for US$225M upfront, plus up to US$55M in milestone payments, expected to close by the end of 2025. more ➔
Boehringer IngelheimPartnershipBoehringer Ingelheim in US$570m deal with CDR-LifeBoehringer Ingelheim has licenced global rights for CDR111, an antibody-based trispecific M-gager to treat autoimmune diseases from CDR-Life, Inc. CDR111 is an antibody-based T-cell engager designed … more ➔
adobe stock photos - MikeCS Images Retinal diseasesAAVantgarde secures $141m Series B fundingAAVantgarde Bio has closed a $141M (€122M) Series B financing round led by Schroders Capital, Atlas Venture, and Forbion. New investors included Amgen Ventures, Athos Capital, CDP Venture Capital, … more ➔
Adobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/M&ANovo and Pfizer in Metsera takeover battleDanish Novo Nordisk A/S has made an unexpected takeover bid for US biotech Metsera, Inc. This challenges the already agreed acquisition by Pfizer Inc. Novo offers US$6.5bn in cash, plus up to US$2.5bn … more ➔
NATODefenceNATO elevates biotech to defence priorityThe NATO is clearly priorising biotech to a defence priority with an annual budget of potentially up to €500m for biotech start-ups starting from 2026. At the opening of the first ever NATO Biotechnology … more ➔
adobe stock photos - Justlight
stock.adobe.photos.com - gavi
adobe stock photos - AkuAku 
Adobe stock photos - Dzmitry 
Adobe stock photos - Matthew 
Parse Biosciences
Boehringer Ingelheim
adobe stock photos - MikeCS Images 
Adobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/
NATO